Last reviewed · How we verify
Avandia (ROSIGLITAZONE)
Avandia (Rosiglitazone) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, a small molecule modality developed by SB Pharmco and currently owned by Woodward. It targets CDGSH iron-sulfur domain-containing protein 1 and was FDA-approved in 1999 for the treatment of type 2 diabetes mellitus. As an off-patent medication, Avandia is available as a generic. Key safety considerations include its potential to increase the risk of heart failure and fractures. Avandia has a half-life of 3.9 hours and high bioavailability of 99%.
At a glance
| Generic name | ROSIGLITAZONE |
|---|---|
| Sponsor | Woodward |
| Drug class | Peroxisome Proliferator Receptor gamma Agonist |
| Target | CDGSH iron-sulfur domain-containing protein 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
- Treatment Refractory Type 2 Diabetes Mellitus
Common side effects
- Nausea/Vomiting
- Anemia
- Edema
- Diarrhea
- Headache
- Dyspepsia
- Hypoglycemia (rosiglitazone + metformin)
- Hypoglycemia (rosiglitazone + insulin)
- Edema (rosiglitazone + insulin)
- Edema (rosiglitazone + metformin)
Serious adverse events
- Congestive Heart Failure
- Myocardial Infarction
- Myocardial Ischemia
- Sudden Death
- Fractures (women)
Drug interactions
- choline fenofibrate
- ciprofloxacin
- fenofibrate
- levofloxacin
- norfloxacin
- ofloxacin
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (PHASE2)
- Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus (PHASE1)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Rosiglitazone Adjunctive Therapy for Severe Malaria in Children (NA)
- BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam (PHASE1)
- Rosiglitazone in Treating Patients With Liposarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avandia CI brief — competitive landscape report
- Avandia updates RSS · CI watch RSS
- Woodward portfolio CI